Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1.

ABSTRACT:

Objectives

The aim of this study was to understand how demographic and treatment-related factors impact responses to fostemsavir-based regimens.

Design

BRIGHTE is an ongoing phase 3 study evaluating twice-daily fostemsavir 600 mg and optimized background therapy (OBT) in heavily treatment-experienced individuals failing antiretroviral therapy with limited treatment options (Randomized Cohort 1-2 and Nonrandomized Cohort 0 fully active antiretroviral classes).

Methods

Virologic response rates (HIV-1 RNA <40 copies/ml, Snapshot analysis) and CD4+ T-cell count increases in the Randomized Cohort were analysed by prespecified baseline characteristics (age, race, sex, region, HIV-1 RNA, CD4+ T-cell count) and viral susceptibility to OBT. Safety results were analysed by base

SUBMITTER: Ackerman P 

PROVIDER: S-EPMC8183480 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature